SG Americas Securities LLC Makes New Investment in Disc Medicine, Inc. $IRON

SG Americas Securities LLC acquired a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 8,064 shares of the company’s stock, valued at approximately $533,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CWM LLC raised its position in Disc Medicine by 213.5% during the second quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after buying an additional 181 shares in the last quarter. Avanza Fonder AB lifted its position in Disc Medicine by 54.0% in the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after buying an additional 585 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Disc Medicine by 8.9% in the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after buying an additional 206 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Disc Medicine by 383.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after buying an additional 3,152 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Stock Down 2.4%

Shares of NASDAQ:IRON opened at $76.33 on Friday. The firm has a market capitalization of $2.88 billion, a P/E ratio of -14.27 and a beta of 0.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The stock has a 50 day moving average price of $84.39 and a 200-day moving average price of $73.16. Disc Medicine, Inc. has a 52-week low of $30.82 and a 52-week high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.29). As a group, equities research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Transactions at Disc Medicine

In related news, insider William Jacob Savage sold 13,093 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $91.22, for a total value of $1,194,343.46. Following the completion of the transaction, the insider directly owned 75,702 shares in the company, valued at $6,905,536.44. This trade represents a 14.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin Bitterman sold 754 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $91.47, for a total transaction of $68,968.38. Following the completion of the sale, the director owned 14,013 shares in the company, valued at approximately $1,281,769.11. This trade represents a 5.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 275,470 shares of company stock worth $24,966,170. 3.64% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th. National Bankshares set a $153.00 price target on shares of Disc Medicine in a research note on Friday, October 17th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wedbush reissued an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Finally, Cantor Fitzgerald increased their target price on Disc Medicine from $132.00 to $153.00 and gave the company an “overweight” rating in a report on Friday, October 17th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus target price of $119.45.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.